SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway

The mammalian target of rapamycin (mTOR) is extensively involved in multiple myeloma (MM) pathophysiology. In the present study, we reported a novel small molecule SC06 that induced MM cell apoptosis and delayed MM xenograft growth in vivo. Oral administration of SC06 to mice bearing human MM xenogr...

Full description

Bibliographic Details
Main Authors: Han, Kunkun, Xu, Xin, Xu, Zhuan, Chen, Guodong, Zeng, Yuanying, Zhang, Zubin, Cao, Biyin, Kong, Yan, Tang, Xiaowen, Mao, Xinliang
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556980/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556980/

Similar Items